Study Design

Previously published in《The research data from the NEJM shows that the trial has reached its primary endpoint:Compared with the osimertinib monotherapy group, the median progression-free survival (PFS) was significantly prolonged in the amivantamab + lazertinib group (23.7 months vs 16.6 months; HR 0.70; 95% CI 0.58-0.85; P<0.001).。

2025 ELCC ConferenceThe latest disclosed overall survival (OS) data show that, at a median follow-up of 37.8 months,Compared with the osimertinib monotherapy group, the median overall survival (OS) in the amivantamab + lazertinib groupExtended by at least 12 months(Not reached vs 36.7 months; HR 0.75; 95% CI 0.61-0.92; P<0.005).

OS Data

OS Subgroup Data

Other key data:1）Time to Symptomatic Progression (TTSP): The combination group and the osimertinib group were respectively:43.6 months vs 29.3 months (HR=0.69; P<0.001).2）Intracranial Progression-Free Survival (icPFS): Median icPFS: Combination group and Osimertinib group, respectively25.4 months vs 22.2 months (HR=0.79; P=0.07); 3-year icPFS rate: Combination group and Osimertinib group, respectively36% vs 18% (Significant Difference).3）Treatment Crossover and Subsequent Therapy: The trial did not allow crossover from the osimertinib group to the combination group, but the proportion of patients receiving subsequent therapy was similar in both groups. In the combination group, 74% received subsequent therapy (chemotherapy 56%, TKI 39%), while in the osimertinib group, 76% received subsequent therapy (chemotherapy 67%, TKI 28%).

Time to Symptomatic Progression (TTSP)